State Street’s Sutro Biopharma STRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.2M | Buy |
305,979
+253,861
| +487% | +$7.92M | ﹤0.01% | 2696 |
|
|
2026
Q1 | $1.3M | Buy |
52,118
+17,852
| +52% | +$323K | ﹤0.01% | 3426 |
|
|
2025
Q4 | $396K | Buy |
34,266
+1
| +0% | +$9 | ﹤0.01% | 3740 |
|
|
2025
Q3 | $298K | Hold |
34,265
| – | – | ﹤0.01% | 3791 |
|
|
2025
Q2 | $245K | Sell |
34,265
-133,969
| -80% | -$1.1M | ﹤0.01% | 3779 |
|
|
2025
Q1 | $1.09M | Sell |
168,234
-1,953
| -1% | -$30.8K | ﹤0.01% | 3408 |
|
|
2024
Q4 | $3.13M | Buy |
170,187
+5,471
| +3% | +$167K | ﹤0.01% | 3159 |
|
|
2024
Q3 | $5.7M | Buy |
164,716
+8,185
| +5% | +$321K | ﹤0.01% | 2901 |
|
|
2024
Q2 | $4.59M | Buy |
156,531
+36,859
| +31% | +$1.46M | ﹤0.01% | 2964 |
|
|
2024
Q1 | $6.76M | Buy |
119,672
+3,525
| +3% | +$156K | ﹤0.01% | 2796 |
|
|
2023
Q4 | $4.98M | Buy |
116,147
+5,568
| +5% | +$177K | ﹤0.01% | 2944 |
|
|
2023
Q3 | $3.84M | Buy |
110,579
+1,167
| +1% | +$50.8K | ﹤0.01% | 3049 |
|
|
2023
Q2 | $5.09M | Sell |
109,412
-182,859
| -63% | -$9.1M | ﹤0.01% | 2988 |
|
|
2023
Q1 | $13.5M | Buy |
292,271
+107,142
| +58% | +$6.8M | ﹤0.01% | 2482 |
|
|
2022
Q4 | $15M | Buy |
185,129
+102,340
| +124% | +$7.11M | ﹤0.01% | 2446 |
|
|
2022
Q3 | $4.59M | Buy |
82,789
+2,430
| +3% | +$144K | ﹤0.01% | 3102 |
|
|
2022
Q2 | $4.19M | Sell |
80,359
-183,890
| -70% | -$10.3M | ﹤0.01% | 3184 |
|
|
2022
Q1 | $21.7M | Buy |
264,249
+105,165
| +66% | +$10M | ﹤0.01% | 2333 |
|
|
2021
Q4 | $23.7M | Sell |
159,084
-11,151
| -7% | -$2M | ﹤0.01% | 2349 |
|
|
2021
Q3 | $32.2M | Sell |
170,235
-53,134
| -24% | -$10.1M | ﹤0.01% | 2136 |
|
|
2021
Q2 | $41.5M | Sell |
223,369
-28,047
| -11% | -$5.49M | ﹤0.01% | 1992 |
|
|
2021
Q1 | $57.2M | Buy |
251,416
+206,139
| +455% | +$48.9M | ﹤0.01% | 1643 |
|
|
2020
Q4 | $9.83M | Buy |
45,277
+12,877
| +40% | +$2.13M | ﹤0.01% | 2636 |
|
|
2020
Q3 | $3.26M | Buy |
32,400
+11,689
| +56% | +$1.1M | ﹤0.01% | 3001 |
|
|
2020
Q2 | $1.61M | Buy |
20,711
+2,850
| +16% | +$273K | ﹤0.01% | 3268 |
|
|
2020
Q1 | $1.82M | Buy |
17,861
+914
| +5% | +$96.1K | ﹤0.01% | 3102 |
|
|
2019
Q4 | $1.86M | Buy |
16,947
+1,363
| +9% | +$141K | ﹤0.01% | 3275 |
|
|
2019
Q3 | $1.42M | Buy |
15,584
+718
| +5% | +$72.5K | ﹤0.01% | 3326 |
|
|
2019
Q2 | $1.69M | Buy |
14,866
+6,129
| +70% | +$675K | ﹤0.01% | 3299 |
|
|
2019
Q1 | $995K | Buy |
8,737
+6,408
| +275% | +$667K | ﹤0.01% | 3340 |
|
|
2018
Q4 | $210K | Buy |
+2,329
| New | +$281K | ﹤0.01% | 3570 |
|
Other funds holding STRO
PA
BI
AAA
SB
KCM
O
EAM
State Street's STRO Position: Q2 2026 in Review
State Street increased its Sutro Biopharma (STRO) stake by 487% in Q2 2026, buying an estimated $7.92M and bringing the position to 305,979 shares worth $10.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2696.
State Street first reported a position in STRO in Q4 2018 and has held it in 31 quarters since. The position peaked at $57.2M in Q1 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.
- State Street held 305,979 shares of Sutro Biopharma worth $10.2M as of Q2 2026.
- State Street bought 253,861 Sutro Biopharma shares in Q2 2026, an estimated $7.92M.
- Sutro Biopharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2696 holding.
- State Street first reported a position in Sutro Biopharma in Q4 2018 and has held it in 31 quarters since.
- State Street's Sutro Biopharma position peaked at $57.2M in Q1 2021.
- 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.